阿仑膦酸盐和唑来膦酸治疗原发性骨质疏松症患者的临床效果  

Clinical Effects of Alendronate and Zoledronic Acid in the Treatment of Patients with Primary Osteoporosis

作　　者：胡彩杰 HU Cai-Jie(Shenyang Orthopaedic Hospital,Shanghai 110044,China)

机构地区：[1]沈阳市骨科医院,沈阳110044

出　　处：《中国药物经济学》2020年第8期86-89,共4页China Journal of Pharmaceutical Economics

摘　　要：目的探讨阿仑膦酸盐、唑来膦酸治疗原发性骨质疏松症(POP)患者的临床效果。方法选取沈阳市骨科医院2017年1月至2019年12月收治的84例POP患者作为研究对象,按治疗方法不同分为对照组和观察组,各42例,对照组采用阿仑膦酸盐治疗,观察组采用阿仑膦酸盐+唑来膦酸治疗。比较两组治疗效果。结果治疗前,两组股骨颈、全髋、腰椎L1-4的骨密度(BMD)比较,差异无统计学意义(P>0.05);治疗后,观察组股骨颈、全髋、腰椎L1-4的BMD高于对照组,差异有统计学意义(P<0.05)。两组治疗前的骨碱性磷酸酶(BALP)、血清Ⅰ型胶原交联羧基末端肽(CTX-Ⅰ)、1,25-二羟维生素D3比较差异无统计学意义(P>0.05);治疗后,观察组BALP、CTX-Ⅰ低于对照组,1,25-二羟维生素D3高于对照组,差异有统计学意义(P<0.05)。观察组临床治疗有效率95.24%高于对照组73.81%,差异有统计学意义(P<0.05)。结论对于POP患者采用阿伦膦酸盐联合唑来膦酸可提高患者BMD,有效改善血生化指标,获得满意疗效。Objective To explore the clinical effects of alendronate and zoledronic acid in the treatment of patients with primary osteoporosis(POP).Methods A total of eight-four patients with primary osteoporosis treated in the Shenyang Orthopaedic Hospital from January 2017 to December 2019 were selected as the research objects and were divided into a control group and an observation group according to different treatment methods,with forty-two cases in each group.The control group was treated with Alendronate and the the observation group was treated with alendronate+zoledronic acid.The curative effects were compared between the two groups.Results Before treatment,the bone mineral density(BMD)of femoral neck,total hip,and lumbar spine L1-4 between the two groups was not significantly different(P>0.05);after treatment,BMD of total hip,and lumbar spine was higher than the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in bone alkaline phosphatase(BALP),serum type I collagen cross-linked carboxy terminal peptide(CTX-I),and 1,25-dihydroxyvitamin D3(P>0.05);after treatment,BALP and CTX-I in the observation group were lower than those in the control group,and 1,25-dihydroxyvitamin D3 was higher than the control group,the difference was statistically significant(P<0.05).The clinical treatment effective rate in the observation group was 95.24%higher than that in the control group 73.81%,and the difference was statistically significant(P<0.05).Conclusion For patients with POP,the use of alendronate combined with zoledronic acid can effectively improve BMD of patients,blood biochemical parameters and achieve satisfactory results.

关 键 词：阿仑膦酸盐 唑来膦酸 原发性骨质疏松症 临床效果 

分 类 号：R591.1[医药卫生—内科学] R977.5[医药卫生—临床医学]